logo_new@0,75x
  • Glycotest
  • About us
    • Management Team and Board
    • Scientific and Medical Advisors
    • Glycotest Investor Presentation
    • Investors
  • Technology
    • Clinical Data
    • Intellectual Property
  • News
  • Contact us
glycotest_logo
logo_new@0,75x
  • Glycotest
  • About us
    • Management Team and Board
    • Scientific and Medical Advisors
    • Glycotest Investor Presentation
    • Investors
  • Technology
    • Clinical Data
    • Intellectual Property
  • News
  • Contact us

Glycotest’s Patent Portfolio Covering Important Asian Liver Disease Diagnostic Market Grows through Grant of Hong Kong Patent.

June 19, 2019
-
News
-
No comments
-
Posted by glycotest
← PREVIOUS POST
Glycotest’s Coverage of Key Biomarker Fucosylated Kininogen Extended by European Patent.
NEXT POST →
Glycotest Announces Start of Enrollment in Its Case-Control Study of the HCC Panel vs AFP for the Detection of Early-stage Hepatocellular Carcinoma (NCT03878550).

Leave a Comment

Your feedback is valuable for us. Your email will not be published.
Cancel Reply

Please wait...
Submit Comment

Related News

Other posts that you should not miss.

Six new patents protecting Glycotest’s HCC Panel test have been issued or allowed in the United States, Europe, China, Taiwan, Japan, and Mexico.

March 1, 2023
-
News
Read More →
Posted by glycotest
1 MIN READ

Glycotest’s Patent Portfolio Covering Detection of Serious Liver Disease Expanded by Grant of European Patent.

January 13, 2021
-
News
Read More →
Posted by glycotest
1 MIN READ

More than 50 Glycotest Fucosylated Biomarkers Protected through Grant of New US Patent.

November 3, 2020
-
News
Read More →
Posted by glycotest
1 MIN READ

GET IN TOUCH

Give Us A Call

+1 484-431-3483

Send Us A Message

info@glycotest.com

Copyright© All Rights Reserved
Website Designed & Developed by Jason and Company
Glycotest’s Patent Portfolio Covering Important Asian Liver Disease Diagnostic Market Grows through Grant of Hong Kong Patent. | Glycotest Diagnostics